SCHEMBL5314248

SCHEMBL5314248

NC(=O)c1cnc2ccncc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.51
SIRT3 Q9NTG7 2/20 0.46
F7 P08709 1/20 0.46
F3 P13726 1/20 0.46
SARM1 Q6SZW1 1/20 0.46
SIRT2 Q8IXJ6 1/20 0.46
SIRT6 Q8N6T7 1/20 0.46
SIRT1 Q96EB6 1/20 0.46
SIRT5 Q9NXA8 1/20 0.46
SIRT4 Q9Y6E7 1/20 0.46
PSMD14 O00487 1/20 0.45
STAMBP O95630 1/20 0.45
COPS5 Q92905 1/20 0.45
MGAM O43451 1/20 0.45
NNMT P40261 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
DYRK1A Q13627 2/20 0.41
CHEK1 O14757 1/20 0.41
AURKA O14965 1/20 0.41
DAPK3 O43293 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721917 0.86 HPGDS (0.55) HPGDSSIRT3F7F3SARM1
Isoquinoline SCHEMBL28230213 0.85 MGAM (0.56) HPGDSSIRT3F7F3SARM1
SCHEMBL3787407 0.84 MGAM (0.64) PSMD14MGAMKDM4ECSNK2A2CSNK2B
SCHEMBL5405254 0.80 HPGDS (0.55) HPGDSPSMD14STAMBPCOPS5MGAM
SCHEMBL12076107 0.79 ALOX15 (0.54) HPGDSPSMD14KDM4EHTTCSNK2A2
SCHEMBL29598071 0.79 ALOX15 (0.54) HPGDSPSMD14KDM4EHTTCSNK2A2
SCHEMBL29362497 0.79 MGAM (0.71) HPGDSPSMD14STAMBPCOPS5MGAM
SCHEMBL23372 0.79 MGAM (0.71) HPGDSPSMD14STAMBPCOPS5MGAM
Hydrochloric Acid SCHEMBL5311903 0.77 MGAM (0.69) HPGDSPSMD14STAMBPCOPS5MGAM
Hydrochloric Acid SCHEMBL28841803 0.77 MGAM (0.69) HPGDSPSMD14STAMBPCOPS5MGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4352059-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2024-04-17 EP disclosed
WO-2022261160-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2022-12-15 WO disclosed
EP-4045502-A1 PHOTOCHEMICAL PROCESS FOR PRODUCING (4R,4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDIN-3-CARBOXAMIDE Bayer Aktiengesellschaft (DE) 2022-08-24 EP disclosed
US-11149035-B2 Chemical compounds as H—PGDS inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED (GB) 2021-10-19 US disclosed
WO-2021074079-A1 PHOTOCHEMICAL PROCESS FOR PRODUCING (4R,4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDIN-3-CARBOXAMIDE BAYER AKTIENGESELLSCHAFT (DE) 2021-04-22 WO disclosed
US-20210024490-A1 METHOD FOR THE PREPARATION OF THE METABOLITES OF (4S)- AND (4R)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE AND THE USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-01-28 US disclosed
CN-108137587-B Method for preparing and recovering amide compound 拜耳制药股份公司 2020-10-23 CN disclosed
US-20200123152-A1 Chemical Compounds as H-PGDS Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-04-23 US disclosed
CN-110753692-A Chemical compounds as H-PGDS inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2020-02-04 CN disclosed
CN-110511219-A The dihydronaphthridine class compound and application thereof that phenyl replaces GUANGDONG HEC PHARMACEUTICAL 2019-11-29 CN disclosed
US-10392384-B2 Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and recovery of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide by electrochemical methods BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-08-27 US disclosed
US-20180244668-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOXAMIDE AND RECOVERY OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOXAMIDE BY ELECTROCHEMICAL METHODS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-08-30 US disclosed
US-20180237414-A1 METHOD FOR THE PREPARATION OF THE METABOLITES OF (4S)- AND (4R)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE AND THE USE THEREOF BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-08-23 US disclosed
CN-108137587-A Method for producing (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyridine-3-carboxamide by means of electrochemical methods and for recovering (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyridine-3-carboxamide 拜耳制药股份公司 2018-06-08 CN disclosed
CN-106795155-A Process for the preparation of (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyridine-3-carboxamide and purification thereof for use as active pharmaceutical active ingredient 拜耳医药股份有限公司 2017-05-31 CN disclosed
US-20070225318-A1 Pyrazole Compounds Useful In The Treatment Of Inflammation BIOLIPOX AB (SE) 2007-09-27 US disclosed
EP-1794145-A1 PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2007-06-13 EP disclosed
WO-2006032851-A1 PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225318-A1 Pyrazole Compounds Useful In The Treatment Of Inflammation ALOX15, ALOX15B, ALOX12 HPGDS 56/4885SIRT3 1347/4885F7 2946/4885
US-11149035-B2 Chemical compounds as H—PGDS inhibitors HPGDS, PTGS1, PTGIS HPGDS 1/4885SIRT3 2173/4885F7 1083/4885
US-10392384-B2 Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and recovery of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide by electrochemical methods MT-ND4, ENTPD1, COX4I1 HPGDS 3397/4885SIRT3 50/4885F7 1899/4885
US-20180244668-A1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOXAMIDE AND RECOVERY OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOXAMIDE BY ELECTROCHEMICAL METHODS MT-ND4, ENTPD1, COX4I1 HPGDS 3397/4885SIRT3 50/4885F7 1899/4885
US-20200123152-A1 Chemical Compounds as H-PGDS Inhibitors HPGDS, PTGS1, PTGIS HPGDS 1/4885SIRT3 2072/4885F7 1023/4885
US-20210024490-A1 METHOD FOR THE PREPARATION OF THE METABOLITES OF (4S)- AND (4R)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE AND THE USE THEREOF CHRM1, CHRM2, CYP4B1 HPGDS 3396/4885SIRT3 143/4885F7 3440/4885
US-20180237414-A1 METHOD FOR THE PREPARATION OF THE METABOLITES OF (4S)- AND (4R)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE AND THE USE THEREOF CHRM1, CHRM2, CYP4B1 HPGDS 3396/4885SIRT3 143/4885F7 3440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.